Epizyme - Crunchbase Company Profile & Funding
David Loew on acquisition of Epizyme
EPZM - Epizyme Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
10-K
Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q3
Epizyme - Crunchbase Company Profile & Funding
Ipsen acquires Epizyme - Medical Buyer
Epizyme accepts reality | Evaluate
rprx-20211231rpplcpressx
Why Epizyme Is Getting Crushed Today | The Motley Fool
Dire straits detailed for Epizyme before buyout by Ipsen
Epizyme Posts Positive Interim Data for Follicular Lymphoma Treatment, Despite Partial Clinical Hold | BioSpace
Articles about Epizyme
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology | Business Wire
FDA Lifts Holds on Epizyme Cancer Candidate - Healthcare Weekly
Histone-writer cancer drugs enter center stage | Nature Biotechnology
Ipsen to acquire Epizyme, expanding its portfolio in oncology | Business Wire
Epizyme's Erin Graves Talks about PR Pals Talk Shop and Shares Networking Tips - Video for Broadcast
ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncom-
Epigenetic Market Report involving Key Players: Abcam Plc.,
Ipsen agrees to buy biopharmaceutical company Epizyme for $247m
Soft Tissue Sarcoma Pipeline, Clinical Trials, FDA Approvals,
Ipsen snaps up Epizyme and cancer drug Tazverik for $247M
Ipsen acquiert Epizyme et étend son portefeuille en Oncologie
